News

Engineered Lipid-based Nanoparticles Therapeutic Delivery System Act as Therapies for Genetic Disorders in Animal Model

Nov, 2021 - By WMR

Engineered Lipid-based Nanoparticles Therapeutic Delivery System Act as Therapies for Genetic Disorders in Animal Model

According to a new study by the researchers of Ohio State University have suggested that lipid-based nanoparticles engineered by them including two sets of protein-making instructions exhibited potential to solve genetic disorders in animals acting as therapies.

Yizhou Dong, senior author, Ohio State University stated,  “We demonstrated two applications for lipid-like nanomaterials that effectively deliver their cargo, appropriately biodegrade and are well-tolerated," said. With this work, we have lowered potential side effects and toxicity, and have broadened the therapeutic window. This gives us confidence to pursue studies in larger animal models and future clinical trials.”

Researchers designed these nanoparticles with an objective of targeting disorders involving genes that are articulated in the liver. The research team underwent with several experiments for several structural changes to those nanoparticles, as they have to transport molecules to the targeted location, releasing the messenger RNA safely at the right time. These experiments were carried out on a mouse model. In the first experiment mouse models for hemophilia and normal mouse were injected with nanoparticles with specific RNA to produce human factor VIII that aids in clotting the blood. Researchers observed that within 12 hours’ time, the mouse with deficiency of human factor VIII produced enough protein to reach 90% of normal activity and also found that there was no scenario of organ damage in both the mouse models.

In the second experiment, researchers loaded nanoparticles with two types of instructions: messenger RNA carrying the genetic code for a DNA base editor, and a guide RNA to make sure the changes took place in a specific gene in the liver known as PCSK9. Further analysis exhibited that the treatment resulted in the planned mutation of about 60% of the target base pairs in the PCSK9 gene, and established that only low dose was needed to get desired results. Researchers also reported that this technology are under process for further clinical development.

Happy To Assist You

Contact Images

We will be happy to help you find what you need. Please call us or write to us:

Contact us

mapicon
Sales Office (U.S.):
Worldwide Market Reports, 1001 4th Ave, #3200 Seattle, WA 98154, U.S.

mapicon+1-415-871-0703

mapicon
Asia Pacific Intelligence Center (India):
Worldwide Market Reports 203, 2nd Floor, Bremen Business Center, Aundh, Pune, Maharashtra 411007, India.

Newsletter

Want us to send you latest updates of the current trends, insights, and more, signup to our newsletter (for alerts, special offers, and discounts).

Secure Payment By:
paymenticon

This website is secured Origin CA certificate on the server, Comodo, Firewall and Verified Sitelock Malware Protection

secureimg

© 2021 Worldwide Market Reports. All rights reserved